Page last updated: 2024-09-05

senicapoc and Hemolysis

senicapoc has been researched along with Hemolysis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW1
Ataga, KI; Stocker, J1
Ataga, KI; Ballas, SK; Bigelow, C; Galacteros, F; Hull, JH; James, LS; Kutlar, A; Reid, M; Smith, WR; Stocker, JW; Yasin, Z1

Reviews

1 review(s) available for senicapoc and Hemolysis

ArticleYear
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:2

    Topics: Acetamides; Anemia, Sickle Cell; Animals; Animals, Genetically Modified; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hemolysis; Humans; Mice; Trityl Compounds

2009

Trials

1 trial(s) available for senicapoc and Hemolysis

ArticleYear
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapo
    British journal of haematology, 2011, Volume: 153, Issue:1

    Topics: Acetamides; Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Drug Administration Schedule; Erythrocyte Aging; Female; Hematocrit; Hemolysis; Humans; Intermediate-Conductance Calcium-Activated Potassium Channels; Male; Middle Aged; Pain; Treatment Outcome; Trityl Compounds; Young Adult

2011

Other Studies

1 other study(ies) available for senicapoc and Hemolysis

ArticleYear
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
    British journal of haematology, 2021, Volume: 192, Issue:5

    Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds

2021